Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10195159 | GW RES LTD | Processes and apparatus for extraction of active substances and enriched extracts from natural products |
May, 2022
(10 months ago) | |
US11096905 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Oct, 2035
(12 years from now) | |
US11207292 | GW RES LTD | Cannabidiol preparations and its uses |
Apr, 2039
(16 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9956186 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
US10092525 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
US9956183 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
US10111840 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
US10137095 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
US10603288 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
US10709671 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
US10709674 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
US9956184 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
US9956185 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
US9949937 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
US10849860 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
US10966939 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
US10709673 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
US11154516 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
US11357741 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
US11311498 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
US11446258 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
US10918608 | GW RES LTD | Use of cannabidiol in the treatment of epilepsy |
Oct, 2035
(12 years from now) | |
US11400055 | GW RES LTD | Use of cannabidiol in the treatment of epilepsy |
Oct, 2035
(12 years from now) | |
US11065209 | GW RES LTD | Use of cannabidiol in the treatment of epilepsy |
Oct, 2035
(12 years from now) | |
US11406623 | GW RES LTD | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
Mar, 2041
(17 years from now) | |
US11160795 | GW RES LTD | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
Mar, 2041
(17 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Sep 28, 2023 |
Orphan Drug Exclusivity (ODE) | Jul 31, 2027 |
New Patient Population (NPP) | Jul 31, 2023 |
NCE-1 date: 2022-09-28
Market Authorisation Date: 28 September, 2018
Treatment: Use for the treatment of convulsive seizures in patients with lennox gastaut syndrome; Use for the treatment of drop seizures in patients with dravet syndrome; Use in combination with clobazam for the...
Dosage: SOLUTION;ORAL
42
United States
21
United Kingdom
15
Australia
15
Japan
10
European Union
9
Mexico
9
Canada
8
Israel
5
Brazil
4
Spain
3
Poland
3
China
2
Denmark
2
Hong Kong
2
Slovenia
2
Lithuania
2
Hungary
2
Croatia
2
Portugal
2
Korea, Republic of
2
RS
1
Austria
1
Taiwan, Province of China
1
EA
1
New Zealand
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic